< Back to search
Filter
1

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis,
Location: Boston MA, Lake Success NY, The Bronx NY, Brooklyn NY,
Sponsor: Kartos Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06479135

Phase3, Recruiting

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

for
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06327100

Phase1, Phase2, Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

for
Myelofibrosis
Location: New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Kartos Therapeutics, Inc.

Sex: All

Age: 18 - 70+

Code: NCT04485260

Phase1, Phase2, Recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

for
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT06218628

Phase1, Recruiting

Interested in new essential thrombocythemia trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image